We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
Cap. Flow
+$12.3M
Cap. Flow %
0.52%
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$32.6M
2
LLY icon
Eli Lilly
LLY
+$25.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
5
WELL.PRI
Welltower Inc.
WELL.PRI
+$11.7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$58.6M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$38.9M
3
ILMN icon
Illumina
ILMN
+$13.4M
4
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$12.5M
5
ALR
Alere Inc
ALR
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 87.12%
2 Real Estate 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTR icon
26
Ventas
VTR
$44.7B
$23.2M 0.99%
369,266
– –
DOC
27
DELISTED
PHYSICIANS REALTY TRUST
DOC
$22.9M 0.97%
1,230,772
– –
MOH icon
28
Molina Healthcare
MOH
$10.2B
$22.4M 0.95%
347,901
– –
MPT
29
Medical Properties Trust
MPT
$2.81B
$20.3M 0.86%
1,564,060
– –
ACAD icon
30
Acadia Pharmaceuticals
ACAD
$4.55B
$20M 0.85%
715,299
+77,799
+12% +$1.7M
ALKS icon
31
Alkermes
ALKS
$8.39B
$19.9M 0.85%
581,944
+71,500
+14% +$2.82M
MDCO
32
DELISTED
Medicines Co
MDCO
$17.9M 0.76%
564,438
+162,468
+40% +$5.31M
UHS icon
33
Universal Health Services
UHS
$9.88B
$16.8M 0.71%
134,680
+64,380
+92% +$7.24M
NVO
34
Novo Nordisk
NVO
$228B
$16M 0.68%
589,200
– –
XBI icon
35
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$15.2M 0.65%
+294,000
New +$15.3M
IBB icon
36
iShares Biotechnology ETF
IBB
$9.52B
$15M 0.64%
173,010
– –
OHI icon
37
Omega Healthcare
OHI
$15B
$14.6M 0.62%
413,116
– –
STJ
38
DELISTED
St Jude Medical
STJ
$14.1M 0.6%
255,810
– –
MNK
39
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$13.7M 0.58%
223,900
+162,000
+262% +$10.4M
SYK icon
40
Stryker
SYK
$133B
$13.3M 0.57%
123,940
– –
BAX icon
41
Baxter International
BAX
$13.8B
$13.1M 0.56%
319,600
– –
MCK icon
42
McKesson
MCK
$101B
$13M 0.55%
82,862
– –
BMY icon
43
Bristol-Myers Squibb
BMY
$132B
$12.9M 0.55%
202,600
– –
HZNP
44
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$12.4M 0.53%
749,900
– –
WELL.PRI
45
DELISTED
Welltower Inc.
WELL.PRI
$12.4M 0.53%
+200,000
New +$11.7M
NBIX icon
46
Neurocrine Biosciences
NBIX
$18.7B
$12.3M 0.52%
311,460
– –
SNY icon
47
Sanofi
SNY
$103B
$12.2M 0.52%
305,000
– –
TMO icon
48
Thermo Fisher Scientific
TMO
$214B
$12.2M 0.52%
86,395
– –
DHC
49
Diversified Healthcare Trust
DHC
$2.17B
$12M 0.51%
670,504
– –
PRTK
50
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$11.6M 0.49%
762,581
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 88% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
  • Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
  • Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
  • Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
  • Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.